Glioblastoma study: Maintenance Radiotherapy
Official title REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
ClinicalTrials.gov ID: NCT07831772
What this study is testing
- What it's testing
- This study checks if giving one extra dose of radiation after standard treatment is safe and possible to do.
- Who it's for
- Adults who have just been diagnosed with glioblastoma, a type of brain tumor.
- What's involved
- Participants first get standard treatment. About four weeks later, they receive one extra dose of radiation and have blood tests before and after.
- Time commitment
- The study involves standard treatment plus one extra radiation visit and blood draws about four weeks later.
- Time commitment: about 5 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically confirmed diagnosis of glioblastoma according to WHO classification criteria for which standard-of-care surgical resection, concurrent...
- Planning to receive standard-of-care radiotherapy with a biological effective dose of 60 Gy or less in 30 fractions
- Age 18 years or older at the time of consent
- Karnofsky performance status of 70 or higher
- Life expectancy of 3 months or longer
You likely can't join if
- Pregnant or breastfeeding
- Presence of brain stem involvement within the planning target volume from the initial course of standard-of-care radiotherapy
- Prior radiation therapy to the brain
- Contraindication to MRI or CT
- Uncontrolled intercurrent illness, including ongoing or active infection, hypertension, serious cardiac arrhythmia requiring medication, acute...
- Any medical condition or clinical laboratory abnormality that, in the investigator's judgment, precludes safe participation in and completion of the...
See the full eligibility criteria
- Histologically confirmed diagnosis of glioblastoma according to WHO classification criteria for which standard-of-care surgical resection, concurrent temozolomide and radiotherapy, and adjuvant temozolomide is planned
- Planning to receive standard-of-care radiotherapy with a biological effective dose of 60 Gy or less in 30 fractions
- Age 18 years or older at the time of consent
- Karnofsky performance status of 70 or higher
- Life expectancy of 3 months or longer
- Adequate organ function confirmed by laboratory values obtained within 14 days of study enrollment, defined as absolute neutrophil count at least 1.5 × 10\^9/L, platelets at least 50 × 10\^9/L, and hemoglobin at least 8...
- Persons of childbearing potential or with partners of childbearing potential must be willing to use contraception during study treatment
- Concurrent use of other investigative treatment is permitted
- Voluntary written consent prior to the performance of any research-related activity
- Pregnant or breastfeeding
- Presence of brain stem involvement within the planning target volume from the initial course of standard-of-care radiotherapy
- Prior radiation therapy to the brain
- Contraindication to MRI or CT
- Uncontrolled intercurrent illness, including ongoing or active infection, hypertension, serious cardiac arrhythmia requiring medication, acute cardiovascular disease or clinically manifested myocardial insufficiency, or...
- Any medical condition or clinical laboratory abnormality that, in the investigator's judgment, precludes safe participation in and completion of the study or could affect compliance with protocol conduct or...
The study team makes the final eligibility decision.
Where it is enrolling
- Minneapolis, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 5 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Minneapolis, Minnesota, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.